Obicetrapib

DB14890InvestigationalSmall molecule

Obicetrapib is under investigation in clinical trial NCT02241772 (A Study on the Effects of TA-8995 on Lp(a) in Subjects With Elevated Lp(a)).

Mechanism: Pharmacologically active on Cholesteryl ester transfer protein
Curator reviewed
Formula / weight: C₃₂H₃₁F₉N₄O₅ · 722.609 g/mol (avg)
Code names: TA-8995

Resolves to

Compound

UNII8O74K609HNCAS866399-87-3ChEMBLCHEMBL3785197

Structure

InChIKeyNRWORBQAOQVYBJ-GJZUVCINSA-NSMILESCCOC(=O)N1[C@H](CC)C[C@H](N(CC2=CC(=CC(=C2)C(F)(F)F)C(F)(F)F)C2=NC=C(OCCCC(O)=O)C=N2)C2=C1C=CC(=C2)C(F)(F)F

Targets

P11597CETP

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

20Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Obicetrapib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account